Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures

BACKGROUND: Galcanezumab is a monoclonal antibody (mAb) that binds calcitonin gene-related peptide (CGRP) and is indicated for the preventive treatment of migraine. Galcanezumab demonstrated early onset of effect in patients with migraine but it is unknown whether the same holds true for patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwedt, Todd J., Kuruppu, Dulanji K., Dong, Yan, Standley, Katherine, Yunes-Medina, Laura, Pearlman, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992932/
https://www.ncbi.nlm.nih.gov/pubmed/33765912
http://dx.doi.org/10.1186/s10194-021-01230-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992932/
https://www.ncbi.nlm.nih.gov/pubmed/33765912
http://dx.doi.org/10.1186/s10194-021-01230-w

Ejemplares similares